The dopamine receptor D3 (DRD3) is a G protein-coupled receptor predominantly expressed in limbic regions of the brain, such as the nucleus accumbens, striatum, and globus pallidus. It plays a key role in regulating emotional, cognitive, and reward-related behaviors, with implications in neuropsychiatric disorders like addiction, schizophrenia, and Parkinson’s disease. DRD3 antibodies are essential tools for detecting and quantifying this receptor in research. They enable the study of DRD3 expression patterns, localization, and alterations under pathological or pharmacological conditions using techniques like Western blotting, immunohistochemistry, or immunofluorescence. A major challenge in developing DRD3 antibodies lies in ensuring specificity, as DRD3 shares high sequence homology (particularly in transmembrane domains) with the closely related DRD2 receptor. To address this, antibodies are often designed against unique epitopes in the N-terminal extracellular domain or third intracellular loop. These antibodies have advanced studies exploring DRD3's role in modulating dopamine signaling pathways, synaptic plasticity, and behavioral responses. Additionally, they support drug development efforts targeting DRD3 for treating substance use disorders or movement disorders. Recent research also utilizes DRD3 antibodies to investigate receptor dimerization, trafficking, and interactions with ligands or antipsychotic drugs, providing insights into therapeutic mechanisms and disease biomarkers.